前列腺体积和血清前列腺特异性抗原作为急性尿潴留的预测指标。来自三项大型跨国安慰剂对照试验的综合经验。

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.

作者信息

Marberger M J, Andersen J T, Nickel J C, Malice M P, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J

机构信息

Department of Urology, University of Vienna, Austria.

出版信息

Eur Urol. 2000 Nov;38(5):563-8. doi: 10.1159/000020356.

DOI:10.1159/000020356

PMID:11096237

Abstract

OBJECTIVES

We evaluated prostate volume and prostate-specific antigen (PSA) as predictors of acute urinary retention (AUR) in men with benign prostatic enlargement (BPE).

METHODS

Data were pooled from 3 identical 2-year, multinational, multicenter, non-US, placebo-controlled finasteride trials in 4,222 men with BPE and no evidence of prostate cancer.

RESULTS

The 2-year incidence of spontaneous AUR was higher in placebo patients with enlarged prostates (4.2% in men with prostate volume > or =40 ml vs. 1.6% in the <40 ml group) and higher PSA levels (3.9% in men with PSA > or =1.4 ng/ml vs. 0.5% in the <1.4 ng/ml group) at baseline. Finasteride reduced AUR incidence by 61% in men with larger prostates, by 63% in men with higher PSA levels, and by 47% in men with smaller prostates, compared with placebo.

CONCLUSIONS

BPE patients with larger prostate volumes, higher PSA levels and no evidence of prostate cancer have an increased risk of developing AUR and therefore derive the greatest benefit from the risk reduction seen with finasteride therapy.

摘要

目的

我们评估了前列腺体积和前列腺特异性抗原（PSA）作为良性前列腺增生（BPE）男性急性尿潴留（AUR）预测指标的情况。

方法

数据来自3项相同的为期2年的跨国、多中心、非美国的安慰剂对照非那雄胺试验，共纳入4222例BPE男性且无前列腺癌证据。

结果

基线时，安慰剂组中前列腺增大患者的2年自发性AUR发生率更高（前列腺体积≥40 ml的男性为4.2%，而<40 ml组为1.6%），且PSA水平更高（PSA≥1.4 ng/ml的男性为3.9%，而<1.4 ng/ml组为0.5%）。与安慰剂相比，非那雄胺使前列腺较大的男性AUR发生率降低61%，PSA水平较高的男性降低63%，前列腺较小的男性降低47%。